{"id":"xanomeline-enteric-capsule","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By activating these subtypes, xanomeline aims to improve cognitive function and potentially treat conditions such as Alzheimer's disease. However, its exact mechanism of action and therapeutic effects are still being investigated in clinical trials.","oneSentence":"Xanomeline is a muscarinic receptor agonist that targets the M1 and M4 subtypes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:41:08.237Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT07011732","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-07-10","conditions":"Alzheimer Disease","enrollment":352},{"nctId":"NCT06937229","phase":"PHASE3","title":"A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-12-02","conditions":"Alzheimer Disease, Agitation","enrollment":600},{"nctId":"NCT07011745","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-07-16","conditions":"Alzheimer Disease","enrollment":352},{"nctId":"NCT07063342","phase":"PHASE1","title":"A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, and to Explore the Effect of Food After Multiple Doses of Selected Prototypes in Healthy Adult Participants","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-06-27","conditions":"Healthy Volunteers","enrollment":72},{"nctId":"NCT06853171","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2025-04-29","conditions":"Psychiatric Disorders","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BMS-986519","KarX-EC"],"phase":"phase_3","status":"active","brandName":"Xanomeline Enteric Capsule","genericName":"Xanomeline Enteric Capsule","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Xanomeline Enteric Capsule is a small molecule that acts as a muscarinic acetylcholine receptor M4 agonist. It is being studied in clinical trials for the treatment of Alzheimer Disease, Psychiatric Disorders, Agitation, and as a placebo-controlled intervention in a Phase 3 study for the treatment of agitation.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}